Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283009 · ClinicalTrials.gov registry record · Phase 3
Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 584
- Enrollment target
NCT01283009: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT01283009 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 584 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01283009, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 584 participants
- Enrollment target
Study Summary
The goal of the study is to determine whether providing early treatment with a glucocorticoid drug, called methylprednisolone, will improve survival in critically ill patients with severe community-acquired pneumonia (CAP). Pneumonia develops when bacteria and other agents invade the lungs. The body's immune system creates a response to produce inflammation to kill the bacteria. A moderate amount of inflammation is beneficial. But, in patients sick enough to be admitted to the ICU, inflammation is frequently out of control. When the body cannot regulate inflammation vital organs (brain, heart, lung, kidney, liver) may be damaged, contributing to death or residual organ damage for those who survive. Glucocorticoids help reduce inflammation. Recent studies have shown that when the body is unable to produce sufficient amounts of glucocorticoids, inflammation can get out of control. Under these circumstances, glucocorticoids given in small doses may help aid the body's ability to reduce inflammation and improve recovery. In a small preliminary trial, glucocorticoid treatment, in addition to standard antibiotic treatment, sped up recovery from pneumonia. It also decreased the length of hospital stay, and increased survival. This Cooperative Studies Program (CSP) study will be the first large-scale, prospective, randomized clinical trial evaluating whether or not this treatment improves recovery. In this study, at each site, patients with severe CAP will be assigned to one of two treatment groups. One group will receive methylprednisolone and the other will receive a placebo (an inert substance that will look like the drug). The investigators have chosen a total duration of treatment of 20 days (7 days full dose followed by slow reduction over 13 days) to prevent relapse of inflammation and allow the body to recover its own ability to produce glucocorticoid. All patients will also receive standardized management of CAP in accordance with current practice guidelines. The
Interventions
- DRUG Methylprednisolone
- DRUG Inactive Substance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 584 participants |
| Start Date | 2012-01-09 |
| Est. Completion | 2016-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283009
The ClinicalTrials.gov registry entry for NCT01283009 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 584 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methylprednisolone is the first listed.
NCT01283009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283009 about?
NCT01283009 is a clinical study titled "Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)". The goal of the study is to determine whether providing early treatment with a glucocorticoid drug, called methylprednisolone, will improve survival in critically ill patients with severe community-acquired pneumonia (CAP). Pneumonia develops when bacteria and other agents invade the lungs. The body...
What is the current status of trial NCT01283009?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 584 participants. The study started on 2012-01-09. Estimated completion is 2016-08-31.
What interventions are being tested in trial NCT01283009?
The interventions under investigation include: Methylprednisolone (DRUG), Inactive Substance (DRUG).
Who is sponsoring clinical trial NCT01283009?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.